CAHP‐210 dialyzer influence on intra‐dialytic vancomycin removal

• Published in: Nephrology, dialysis, transplantation Vol. 17; no. 9; pp. 1649 - 1654
• Main Authors: Lucksiri, Aroonrut, Scott, Meri K., Mueller, Bruce A., Hamburger, Richard J., Sowinski, Kevin M.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.09.2002
• Subjects: Adult; Aged; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - therapeutic use; Antibacterial agents; antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; biocompatible membrane; Biological and medical sciences; cellulose acetate; cellulose acetate high performance‐210; Cross-Over Studies; cross‐over study; drug removal; Emergency and intensive care: renal failure. Dialysis management; end‐stage renal disease; Equipment Design; Female; glycopeptide; haemodialysis; hemodialyzer; human; Humans; Intensive care medicine; Kidney Failure, Chronic - therapy; Kinetics; Male; Medical sciences; Metabolic Clearance Rate; Middle Aged; pharmacokinetics; Pharmacology. Drug treatments; prospective study; Renal Dialysis - instrumentation; vancomycin; Vancomycin - blood; Vancomycin - pharmacokinetics; Vancomycin - therapeutic use; Human; Kidney disease; Urinary system disease; Peptides; Apheresis; Hemodialysis; Terminal stage; Hemodialyzer; Permeability; Vancomycin; Enzyme immunoassay; Extrarenal dialysis; Dialyzer; Chemotherapy; Treatment; Glycopeptide
• ISSN: 0931-0509; 1460-2385; 1460-2385
• DOI: 10.1093/ndt/17.9.1649

Background. Vancomycin is often administered during the last hour of haemodialysis because it was not removed significantly by older hemodialyzers. However, newer higher permeability hemodialyzers remove vancomycin, although the amount removed varies considerably between dialyzers. The purpose of this study was to determine the apparent amount of vancomycin removed during the last hour of haemodialysis with a CAHP‐210 hemodialyzer. Methods. Eight subjects with end‐stage renal disease (ESRD) received i.v. vancomycin 15 mg/kg after their regular haemodialysis session ended. Serum samples for the determination of vancomycin concentrations were obtained serially for 44 h. After a 3‐week washout, the study was repeated with the vancomycin infused during the last hour of their regular haemodialysis session using a CAHP‐210 hemodialyzer. Vancomycin concentrations were determined by the Enzyme Multiplied Immunoassay Technique. Differential equations describing a two‐compartment open infusion model were fitted to the serum concentration vs time data and pharmacokinetic parameters and apparent vancomycin removal was estimated. Results. The median age and weight of the subjects were 52 years (range 37–71) and 75.6 kg (range 37.6–89.8), respectively. The apparent vancomycin intra‐dialytic removal was 0.24 (range −0.07–0.35), which was statistically significantly different from zero. Conclusions. Vancomycin administered during the last hour of CAHP‐210 dialysis results in 24% less vancomycin exposure than when administered post‐haemodialysis. This intra‐dialytic drug loss should be accounted for when dosing vancomycin in this manner.